PharmAla Biotech forms joint venture for APA-01 drug development

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/18/2026

1. VRNS
2. JBHT
3. CRWV
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. USB
10. SPY

Go back to PharmAla Biotech forms joint venture for APA-01 drug development

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

May 13, 2026 8:30 AM EDT

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (PharmAla or the Company), a leader in the research, development, and manufacturing of clinical-grade MDMA and novel MDXX-class compounds, today announced that it has executed a definitive SPV Formation, Shareholder and License Agreement (the Definitive Agreement) with Aluvaris Inc. (Aluvaris) and Diteba Inc. (Diteba). The Definitive Agreement establishes a jointly-owned special purpose vehicle called Restora Neurosciences (the Restora or the... More